Glaukos Q3 net sales up 10% to $78M; raises FY2023 guidance to $307-310M

GLAUKOS Corp

2023-Q3 EPS reported -$2.03 revenue$232,346,000

Net sales $78.0M (+10% YoY); glaucoma $58.3M (+9%), corneal health $19.7M (+12%).
GAAP net loss $30.4M ($0.63/share); non-GAAP net loss $24.2M ($0.50/share).
Raised FY2023 net sales guidance to $307-310M from $304-308M.
Cash and equivalents $307M at quarter end.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

GLAUKOS Corp reported third quarter ended September 30, 2023 results: revenue $78.0 million, net income ($30.4 million, or ($0.63) per diluted share). Guidance raised.

Period: third quarter ended September 30, 2023
Revenue: $78.0 million
Net income: ($30.4 million, or ($0.63) per diluted share)
Guidance: raised
Result: reported results

Exact text from the filing

of glaucoma, corneal disorders and retinal diseases, today announced financial results for the third quarter ended September 30, 2023. Key highlights include: · Net sales of $78.0 million in Q3 2023 increased 10% year-over-year on a reported basis and 9% year-over-year on a constant currency basis. · Glaucoma net sales of $58.3 million in Q3 2023 increased 9%

View on SEC.gov

Browse all earnings releases →

GLAUKOS Corp filing history →

Source: SEC EDGAR

accession 0001558370-23-017235

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.